# Axi-cel in CNS Lymphoma

> **NCT04608487** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 18 (actual)

## Conditions studied

- Lymphoma
- Lymphoma Cns

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Axicabtagene Ciloleucel

## Key facts

- **NCT ID:** NCT04608487
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-04
- **Primary completion:** 2025-06-14
- **Final completion:** 2038-06-14
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04608487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04608487, "Axi-cel in CNS Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04608487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*